Table I.
Baseline Clinical Characteristics and Medication of the Study Population
| Variable | Irbesartan (n=18) | Control (n=18) | P Value |
|---|---|---|---|
| Age, % | 54±9 | 55±11 | ns |
| Systolic BP, mm Hg | 150±18 | 147±22 | ns |
| Diastolic BP, mm Hg | 88±11 | 89±13 | ns |
| LVMI, g/m2 | 135±35 | 134±29 | ns |
| IMT, mm | 1.058±.34 | 1.003±.46 | ns |
| CFR | 2.87±.42 | 2.94±.61 | ns |
| Comorbid conditions, No. (%) | |||
| Diabetes | 3 (16.7) | 4 (22.2) | ns |
| Dyslipidemia | 7 (38.9) | 6 (33.3) | ns |
| Concomitant medication, No. (%) | |||
| ASA | 7 (38.9) | 9 (50.0) | ns |
| Diuretic | 8 (44.4) | 10 (55.5) | ns |
| β‐Blocker | 5 (27.8) | 6 (33.3) | ns |
| CCB | 5 (27.8) | 6 (33.3) | ns |
| ARB/ACE inhibitor | 0 (0) | 5 (27.8) | <.01 |
| Statin | 5 (27.8) | 6 (33.3) | ns |
Values are mean ± standard deviation unless otherwise indicated. Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin II type I receptor blocker; BP, 24‐h ambulatory blood pressure; CCB, calcium channel blocker; CFR, coronary flow velocity reserve; IMT, intima‐media thickness; LVMI, left ventricular mass index; ns, not significant.